Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01965106 · ClinicalTrials.gov registry record · Phase 2
Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)
A Phase 2 study, sponsored by Quark Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT01965106 is a Phase 2 study that has completed, run by Quark Pharmaceuticals. The registered enrollment target is 46 participants.
The verdict
NCT01965106, a Phase 2 study, has completed, sponsored by Quark Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
This study will assess any side effects that may occur when QPI-1007 is injected into the eye in subjects with acute primary angle-closure glaucoma, as well as how long it takes for the body to clear the drug. This study will also test whether QPI-1007, injected into the eye, helps prevent both structural damage of the nerve tissue in the eye and the loss of visual function in subjects with acute primary angle-closure glaucoma.
Interventions
- DRUG QPI-1007 Injection
- DRUG (including placebo)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2013-12 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01965106
The ClinicalTrials.gov registry entry for NCT01965106 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Quark Pharmaceuticals, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which QPI-1007 Injection is the first listed.
NCT01965106 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01965106 about?
NCT01965106 is a clinical study titled "Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)". This study will assess any side effects that may occur when QPI-1007 is injected into the eye in subjects with acute primary angle-closure glaucoma, as well as how long it takes for the body to clear the drug. This study will also test whether QPI-1007, injected into the eye, helps prevent both stru...
What is the current status of trial NCT01965106?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2013-12. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01965106?
The interventions under investigation include: QPI-1007 Injection (DRUG), (including placebo) (DRUG).
Who is sponsoring clinical trial NCT01965106?
This trial is sponsored by Quark Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.